___

• Ageev, A.K., 1986. Amyloidosis of the pancre- atic islets and diabetes mellitus. Arkh Patol., 48, 11-15.
• Beaumont, K., Kenney, M.A., Young, A.A., Rink, T.J., 1993. High affinity amylin binding sites in rat brain. Mol Pharmacol., 44, 493-497.
• Beeley N.R.A., Prickett K.S., 1996. The amylin, CGRP and calcitonin family of peptides. Expert Opin Ther Pat., 6, 555-567.
• Bhavsar, S.P., Gedulin B.R., Beaumont, K., Rink T.J., Young A.A., 1995. Inhibition of gastric emptying and of food intake appear to be inde- pendently controlled in rodents. Proc aust Neuro- sci., 21, 460.
• Bhavsar, S., Watkins, J., Young A., 1997. Com- parison of central and peripheral administration of amylin on reduction of food intake in rats. Diabetologia, A302.
• Bhavsar, S., Watkins, J., Young, A., 1998. Syn- ergy between amylin and cholecystokinin for in- hibition of food intake in mice. Physiol Behav., 64, 557-561.
• Bronsky, J., Prusa, R., 2003. Amylin fasting plasma levels are decreased in patients with os- teoporosis. Osteoporos Int., 15, 253-247.
• Castle Arthur L, Kuo C.H., IVY J.L., 1997. Amylin influences insulin-stimulated glucose metabolism by two independent mechanism. En- docrinol Metab., 274, 6-12.
• Chance, W.T., Balasubramaniam A., Zhang F.S., Wimalawansa S.J., Fischer J.E. 1991. Anorexia following the intrahypothalamic administration of amylin. Brain Res., 539, 352-354,.
• Cooper, G.J., Willis, A.C., Clark, A., Turner, R.C., Sim, R.B., Reid, K.B., 1987. Putrification and characterization of a peptide from amiloid- rich pancreases of type 2 diabetic patients. P Natl Acad Sci USA., 84, 8628-8632.
• Cooper, G.J.S., Leighton, B., Dimitriadis GD, Parry-Billings M, Kowalchuk, J.M., Howland, K., Rothbard, J.B., Willis, A.C., Reid K.B., 1988. Amylin found in amyloid deposits in human type 2 diabetes mellitus may be a hormone that regu- lates glycogen metabolism in skeletal muscle. P Natl Acad Sci USA., 85, 7763-7766.
• Cooper, M.E., Wookey, P.J., 1997. Amylin-its role in kidney. Nephrol dial transplant.,12, 8-10.
• Fineman, M.S., Weyer, C., Maggs D.G., Strobel S., Kolterman O.G., 2002. The human amylin analog, pramlintide, reduces postprandial hyper- glucagonemia in patients with type 2 diabetes mellitus. Horm Metab Res., 34, 504-508.
• Frank, J.W., Saslow, S.B., Camilleri, M., Thom- forde, G.M., Dinneen, S.F., Rizza, R.A., 1995. Mechanisms of accelerated gastric emptying of liquids and hyperglycemia in patients with type II diabetes mellitus. Gastroenterology, 109, 755- 765.
• Gedulın, B., Percy, A., Jodka, C., Young, A., 1997. Studies using neutralizing antibody and the antagonist AC187 reveal that endogenous amylin inhibits glucagon secretion. Diabetologia, 40, A300.
• Gerich, J.E., Schneider, V., Dippe, S.E., 1974. Characterization of the glucagon response to hy- poglycemia in man. J Clin Endocr Metab., 38, 77-82,
• Gerich, J.E., 1993. Control of glycaemia. Best Pract Res Cl En., 7, 551-586.
• Gren, G.M., Guan, D., Schwartz, J.G., Phillips, W.T., 1997. Accelerated gastric emptying of glu- cose in Zucker type 2 diabetic rats: role in post- prandial hyperglycaemia. Diabetologia, 40, 136- 142.
• Guidobono F., 1998. Amylin and gastrointestinal activity. Genetic Pharmacol., 31, 173-177.
• Hoppener, J.W., Nieuwenhuis, M.G., Vroom, T.M., Ahren, B.O., Lips, C.J., 2002. Role of islet amyloid in type 2 diabetes mellitus: consequence or cause. Mol Cel Endocrinol., 197, 205-212.
• Koda J.E., Fineman, M., Rink, T.J., Dailey, G.E., Muchmore, D.B., Linarelli, L.G., 1992. Amylin concentrations and glucose control. Lancet, 339, 1179-1180.
• Kruger, D.F., Gatcomb, P.M., Owen, S.K., 1999. Clinical implication of amylin and amylin defi- ciency. Diabetes, 25, 389-398.
• Ludvik, B., Kautzky W.A., Prager, R., Thomaseth, K., Pacini, G., 1997. Amylin: history and overview. Diabetic Med., 14, 9-13.
• Min, S.H., Farr, V.C., Lee, J., Prosser, C.G., Cooper, G.J.S., Davis, S.R., 1999. Metabolic ef- fects of amylin in lactating goats. J Anim Sci., 77, 1241-1248.
• Moore C.X., Cooper, G.J.S., 1991. Co-secretion of amylin and insulin from cultured islet beta- cells: modulation by nutrient secretagogues, islet hormones and hypoglycemic agents. Biochem Bioph Res Co., 179, 1-9.
• Nakazato, M., Asai, J., Kangawa, K., Matsukura, S., Matsuo, H., 1989. Establishment of radioim- munoassay for human islet amyloid polypeptide and its tissue content and plasma concentration. Biochem Bioph Res Co., 164, 394-399.
• Ogawa, A., Harris, V., Mccorkle, S.K., Unger, R.H., Luskey, K.L., 1990. Amylin secretion from the rat pancreas and its selective loss after strep- tozotocin treatment. J Clin Invest., 85, 973-976.
• Reda, T.K., Geliebter, A., Pı-Sunyer F.X., 2002. Amylin, food intake, and obesity. Obes Res., 10, 1087-1091.
• Silvestre, R.A., Rodriguez-Gallardo, J., Jodka, C., Parkes, D.G., Pittner, R.A., Young, A.A., Marco, J., 2001. Selective amylin inhibition of the glucagon response to arginine is extrinsic to the pancreas. Anim J Physiol Endocrinol Metab., 280, 443-449.
• Tamura, T., Miyaura, C., Owan, I., Suda, T., 1992. Mechanism of action of amylin in bone. J Cell Physiol., 153, 6-14.
• Unger, R.H., Orci, L., 1977. The role of glucagon in the endogenous hyperglycemia of diabetes mellitus. Annu Rev Med., 28, 119-130.
• Van, R.D., Menard D.P., Fournier, A., St Pierre S, Quırıon R., 1994. Autoradiographic distribu- tion and receptor binding profile of [I-125]Bolton Hunter-rat amylin binding sites in the rat brain. J Pharmacol Exp Ther., 270, 779-787.
• Westermark, P., Wilander, E., 1983. Islet amy- loid in type 2 non-insulin-dependent diabetes is related to insulin. Diabetologia, 24, 342-346.
• Westermark, P., Wernstedt, C., Wilander, E., Sletten, K., 1986. A novel peptide in the calci- tonin gene related peptide family as an amyloid fibril protein in the endocrine pancreas. Biochem Biophys Res Commun., 140, 827-831.
• Wimalawansa, S.J., 1997. Amylin, calcitonin gene-related peptide, calcitonin, and adrenome- dullin: A peptide superfamily. Crit Rev Neuro- biol., 11, 167-239.
• Young, A.A., Gedulin, B., Vine, W., Percy, A., Rink, T.J., 1995. Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutane- ous injections of amylin. Diabetologia, 28, 642- 648.
• Young, A.A., Gedulin, B.R., Rink, T.J., 1996. Dose-responses for the slowing of gastric empty- ing in a rodent model by glucagon like peptide (7-36)NH2, amylin, cholecystokinin, and other possible regulators of nutrient uptake. Metabo- lism, 45, 1-3.
• Young, A.A., Vine, W., Gedulin, B.R., 1996 Preclinical pharmacology of pramlintide in the rat: comparisons with human and rat amylin. Drug Develop Res., 37, 231-248.
• Young, A., 1997. Amylin's physiology and its role in diabetes. Curr Opin Endocrinol Diab., 282-290.
• Young, A., 1997. Role of amylin in nutrient in- take- animal studies. Diabetic Med., 14, 14-18.
• Young, A., 2005. Historical background. Adv Pharmacol., 52, 1-18.